ALMS announces topline results from Envudeucitinib Phase 2b in SLE
Alumis said it has topline initial high-level results from its Envudeucitinib Phase 2b trial in systemic lupus erythematosus (SLE).
Story updates
11:34:36 AM UTC
SquawkNews
Alumis NASDAQ:ALMS said on Tuesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with a chronic autoimmune disease called systemic lupus erythematosus.
11:37:19 AM UTC
SquawkNews
LUMUS trial did not meet its primary and secondary endpoints in the overall trial population —— Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving forward with Phase 3 development in SLE —— Pharmacodynamic data substantiate en…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.